ZA201904966B - Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer - Google Patents
Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancerInfo
- Publication number
- ZA201904966B ZA201904966B ZA2019/04966A ZA201904966A ZA201904966B ZA 201904966 B ZA201904966 B ZA 201904966B ZA 2019/04966 A ZA2019/04966 A ZA 2019/04966A ZA 201904966 A ZA201904966 A ZA 201904966A ZA 201904966 B ZA201904966 B ZA 201904966B
- Authority
- ZA
- South Africa
- Prior art keywords
- hydrocarbylsulfonyl
- cancer
- treatment
- substituted pyridines
- pyridines
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455641P | 2017-02-07 | 2017-02-07 | |
| US201762594794P | 2017-12-05 | 2017-12-05 | |
| PCT/GB2018/050346 WO2018146472A1 (en) | 2017-02-07 | 2018-02-07 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201904966B true ZA201904966B (en) | 2023-12-20 |
Family
ID=61274298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/04966A ZA201904966B (en) | 2017-02-07 | 2019-07-29 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11161815B2 (enExample) |
| EP (1) | EP3580203A1 (enExample) |
| JP (1) | JP7229176B2 (enExample) |
| KR (1) | KR20190115014A (enExample) |
| CN (1) | CN110382464A (enExample) |
| AU (1) | AU2018218522B2 (enExample) |
| BR (1) | BR112019016248A2 (enExample) |
| CA (1) | CA3051539A1 (enExample) |
| MA (1) | MA47458A (enExample) |
| MX (1) | MX392900B (enExample) |
| RU (1) | RU2019128063A (enExample) |
| WO (1) | WO2018146472A1 (enExample) |
| ZA (1) | ZA201904966B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| US11208384B2 (en) | 2017-02-07 | 2021-12-28 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| EP3580215A1 (en) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| US11161815B2 (en) * | 2017-02-07 | 2021-11-02 | Oblique Therapeutics Ab | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| BR112019016233A2 (pt) | 2017-02-07 | 2020-04-07 | Oblique Therapeutics Ab | piridinas substituídas com heterociclilsulfonila e uso das mesmas no tratamento de câncer |
| WO2019155086A1 (en) * | 2018-02-12 | 2019-08-15 | Cinda Pharma Ab | Thioredoxin reductase inhibitors for use in the treatment of cancer |
| EP4201929B1 (en) * | 2021-12-24 | 2024-08-14 | geneXplain GmbH | Quinoxaline thioredoxin reductase inhibitors |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0031173B1 (en) | 1979-12-19 | 1983-09-14 | Duphar International Research B.V | New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| JPS63166865A (ja) * | 1986-12-22 | 1988-07-11 | バイエル・アクチエンゲゼルシヤフト | 置換されたフエノキシピリジン類 |
| DE3729071A1 (de) * | 1986-12-22 | 1988-06-30 | Bayer Ag | Substituierte phenoxypyridine |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| US5945425A (en) | 1994-04-29 | 1999-08-31 | G.D. Searle & Co. | Method of using (H+ /K+)ATPase inhibitors as antiviral agents |
| JP2002515023A (ja) | 1995-08-24 | 2002-05-21 | ビーエーエスエフ アクチェンゲゼルシャフト | Ｎ−複素環化合物、その製造用中間体、それを含む組成物及び有害菌類防除にそれを使用する方法 |
| DE19531148A1 (de) * | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| DE19531348A1 (de) | 1995-08-25 | 1997-02-27 | Gsf Forschungszentrum Umwelt | Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo |
| WO1998054139A1 (de) | 1997-05-30 | 1998-12-03 | Basf Aktiengesellschaft | Verfahren zur herstellung substituierter thiopyridine |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| WO1999018096A1 (en) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| ES2193607T3 (es) | 1998-01-16 | 2003-11-01 | Hoffmann La Roche | Derivados de benzosulfona . |
| AU2001245353A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AU2003211427A1 (en) | 2002-02-18 | 2003-09-04 | Ishihara Sangyo Kaisha, Ltd. | Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
| US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| MXPA06014129A (es) | 2004-06-04 | 2007-03-07 | Arena Pharm Inc | Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos. |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (en) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Methods of identifying modulators of bromodomains |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| EP1976495A2 (en) | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| JP2009535307A (ja) | 2006-04-28 | 2009-10-01 | アベキサ・リミテッド | インテグラーゼ阻害剤３ |
| US20090005422A1 (en) | 2006-05-22 | 2009-01-01 | Thioredoxin Systems Ab | Bacterial thioredoxin reductase inhibitors and methods for use thereof |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| WO2010007756A1 (ja) * | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Ｔｔｋ阻害作用を有するピリジン誘導体 |
| CN101723932B (zh) * | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| AU2010253820A1 (en) | 2009-05-28 | 2011-12-22 | President And Fellows Of Harvard College | N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation |
| US9567318B2 (en) | 2009-08-17 | 2017-02-14 | Memorial Sloan-Kettering Cancer Center | Substituted pyrimidine compounds and uses thereof |
| US9206125B2 (en) | 2010-02-10 | 2015-12-08 | Public University Corporation Yokohama City University | Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| EP2609089A1 (en) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| WO2013119931A1 (en) | 2012-02-10 | 2013-08-15 | The Board Of Regents Of The University Of Texas System | Modulators of exchange proteins directly activated by camp (epacs) |
| JP6393322B2 (ja) | 2013-07-10 | 2018-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なキラル窒素−リン配位子及びアルケン類の不斉水素化のためのその使用 |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN104672241B (zh) | 2015-01-29 | 2018-04-24 | 王磊 | 吡咯并[2,3-d]嘧啶类化合物及其用途 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| EP3580215A1 (en) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| US11208384B2 (en) | 2017-02-07 | 2021-12-28 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| US11161815B2 (en) * | 2017-02-07 | 2021-11-02 | Oblique Therapeutics Ab | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| BR112019016233A2 (pt) | 2017-02-07 | 2020-04-07 | Oblique Therapeutics Ab | piridinas substituídas com heterociclilsulfonila e uso das mesmas no tratamento de câncer |
-
2018
- 2018-02-07 US US16/484,057 patent/US11161815B2/en not_active Expired - Fee Related
- 2018-02-07 EP EP18707131.1A patent/EP3580203A1/en not_active Withdrawn
- 2018-02-07 CN CN201880010169.1A patent/CN110382464A/zh active Pending
- 2018-02-07 JP JP2019563699A patent/JP7229176B2/ja active Active
- 2018-02-07 MX MX2019009266A patent/MX392900B/es unknown
- 2018-02-07 KR KR1020197024697A patent/KR20190115014A/ko not_active Ceased
- 2018-02-07 BR BR112019016248A patent/BR112019016248A2/pt not_active IP Right Cessation
- 2018-02-07 MA MA047458A patent/MA47458A/fr unknown
- 2018-02-07 RU RU2019128063A patent/RU2019128063A/ru unknown
- 2018-02-07 CA CA3051539A patent/CA3051539A1/en active Pending
- 2018-02-07 AU AU2018218522A patent/AU2018218522B2/en not_active Ceased
- 2018-02-07 WO PCT/GB2018/050346 patent/WO2018146472A1/en not_active Ceased
-
2019
- 2019-07-29 ZA ZA2019/04966A patent/ZA201904966B/en unknown
-
2021
- 2021-10-29 US US17/514,288 patent/US20220119348A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019016248A2 (pt) | 2020-04-14 |
| MX2019009266A (es) | 2019-11-05 |
| MX392900B (es) | 2025-03-24 |
| WO2018146472A1 (en) | 2018-08-16 |
| RU2019128063A3 (enExample) | 2021-05-21 |
| MA47458A (fr) | 2019-12-18 |
| KR20190115014A (ko) | 2019-10-10 |
| US20200239417A1 (en) | 2020-07-30 |
| AU2018218522A1 (en) | 2019-08-15 |
| JP2020506970A (ja) | 2020-03-05 |
| CN110382464A (zh) | 2019-10-25 |
| CA3051539A1 (en) | 2018-08-16 |
| EP3580203A1 (en) | 2019-12-18 |
| AU2018218522B2 (en) | 2021-08-05 |
| RU2019128063A (ru) | 2021-03-09 |
| US11161815B2 (en) | 2021-11-02 |
| US20220119348A1 (en) | 2022-04-21 |
| JP7229176B2 (ja) | 2023-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201904695B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| IL258979B (en) | The use of pyrimidine and pyridine history in the treatment of cancer | |
| IL258725A (en) | Polypeptides with an extracellular cd80 site and their use in cancer therapy | |
| HUE070316T2 (hu) | Királis diaril makrociklus és annak felhasználása rák kezelésében | |
| ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| IL261932A (en) | Use of probiotics in the treatment and/or prevention of eczema | |
| IL258978B (en) | The use of pyrimidine and pyridine derivatives in the treatment of multiple sclerosis | |
| ZA201904967B (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| SG11202104571RA (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| GB201514021D0 (en) | Novel Pyridines and their use in the treatment of cancer | |
| IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
| ZA201704726B (en) | Peptides and their use in the treatment of skin | |
| IL266128B (en) | History of naphthyridinone and its use in the treatment of arrhythmia | |
| GB201820659D0 (en) | Novel compostions and their use in therapy | |
| GB201604213D0 (en) | Drug combination and its use in therapy | |
| ZA201905402B (en) | Compounds and their use in the treatment of schistosomiasis | |
| IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
| IL259358A (en) | Bis-pyridazine compounds and their use in treating cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| GB201514018D0 (en) | Novel tricyclic compounds and their use in the treatment of cancer | |
| PL3752513T3 (pl) | Dwujądrowe palladocykle i ich zastosowanie w leczeniu nowotworów złośliwych | |
| HK40020422A (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| HK40020423A (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| HK40020425A (en) | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer |